Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. - Wikidata - wikimedia - TriplyDB

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

http://www.wikidata.org/entity/Q33607288

about

A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts Synaptic Wnt/GSK3β Signaling Hub in Autism Emerging pharmacologic treatment options for fragile X syndrome Fragile X syndrome and targeted treatment trials.Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.The pathophysiology of fragile X (and what it teaches us about synapses)Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Wnt signaling networks in autism spectrum disorder and intellectual disability Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome Lithium-Responsive Seizure-Like Hyperexcitability Is Caused by a Mutation in the Drosophila Voltage-Gated Sodium Channel Gene paralytic.Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice.Normal Performance of Fmr1 Mice on a Touchscreen Delayed Nonmatching to Position Working Memory Task Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background.From FMRP function to potential therapies for fragile X syndrome.Modeling fragile X syndrome in the Fmr1 knockout mouse Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice.The role of fragile X mental retardation protein in major mental disorders.Hyperactivity, startle reactivity and cell-proliferation deficits are resistant to chronic lithium treatment in adult Nr2e1(frc/frc) mice Potential therapeutic interventions for fragile X syndrome The clinical implications of mouse models of enhanced anxiety.Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model Pharmacological rescue of cortical synaptic and network potentiation in a mouse model for fragile X syndrome GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism.Lithium: a promising treatment for fragile X syndrome.Fragile X targeted pharmacotherapy: lessons learned and future directions.Frontal-subcortical protein expression following prenatal exposure to maternal inflammation.Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome Fragile X syndrome: an update on developing treatment modalities.Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule.Increasing our understanding of human cognition through the study of Fragile X Syndrome.Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment.Concise review: Fragile X proteins in stem cell maintenance and differentiation PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome Perturbation of the Akt/Gsk3-β signalling pathway is common to Drosophila expressing expanded untranslated CAG, CUG and AUUCU repeat RNAs.Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

P2860

Q26741164-14F49782-E6E3-49B1-9362-78CB561E2F55 Q26765504-6A13D7D5-259D-48CC-B7F2-10F00B1C600A Q26829152-C2B31C1B-4D85-4F68-9984-A3E9A55DB932 Q26865162-0B227C5D-55AF-4754-B8BC-A73A5591F4A8 Q26866506-06198FEC-7359-4DE8-8020-B70D8266E3CD Q27010675-73ECA33D-B6AE-4749-941F-B0498B824418 Q27023257-1D838F89-AF33-44D6-B174-9E0244A07DC0 Q27337360-743913C4-C6E6-4BBE-A34B-DA5A610B2D7E Q28074740-F5CC5686-94E5-48CD-B166-DF45200215DE Q28261563-74363216-5AA9-4685-A579-55A4B7DC7E9A Q28585288-E79D4DFA-9FA6-4F36-982A-9DB2CF00D5C9 Q30370008-E5475699-4B65-4A5E-ACD9-43D8265133A3 Q30376422-7BAEA9C2-1E28-42DB-9F9A-306287A77061 Q30387508-BBD8A155-384A-4205-A93E-88AA3221C23C Q30403591-7C7F657D-80B8-486D-BA00-134BE49595DB Q30410502-6074047C-4633-493D-B9AB-3F8FF1483A9A Q30420595-6BC51E04-10D8-418E-AD04-8BE7A6E18B86 Q30456006-D3996E8C-A3A6-4201-AAB9-B372864C2E8A Q30467175-6D464BB7-E783-4358-A75B-B01BD44497C8 Q30469863-F49A1933-474B-4BEF-9CF0-0CEA9E820A51 Q30473378-1E641001-445E-4704-A360-6E8719C51C3F Q30474232-13C450B7-4810-45DB-B448-44E64B84447B Q30474415-16692E95-D3EA-4572-A68D-FCEA57E2550F Q30500501-665183B8-F210-42D8-8BF8-8DA19325366C Q30557514-FBC94D5A-639F-440A-825F-833D483399E6 Q30580825-C6018261-68F6-47B4-8B79-D64CBD1CBB72 Q33543082-D9C591E3-0039-4A4A-92E8-ECF3B4611A33 Q33777951-74D7A3F9-1DAD-4C94-9D1C-ACA09800AF1E Q33785983-E4EEFD6B-38FB-4705-926D-B4F0CD36DDF5 Q33828632-EAEE7C55-A44D-4D6A-8B0B-60D677E33F3C Q34142731-D3A661CA-66CC-42C1-8C0F-7987952A6F8F Q34292108-167E604C-5942-401D-9B7C-10C59B3F03F3 Q34431654-7E5F8083-C8BD-4496-BB5C-3BC84CF15C55 Q34435526-033D487A-3C6E-4857-B8A3-AE5D16426C3A Q34631614-2205C899-414F-4271-83DF-C320A657E2DC Q34632480-0D602F1B-E2F4-486D-9A29-C24E5EED6AAF Q34869830-A454AF3D-F2A5-4353-B98E-0A8295FE3196 Q35056048-0AC70AF2-85E6-4D33-9C21-7F51D6B81511 Q35102732-C284836F-3D1C-44D4-B2BA-3C3BB902697B Q35197096-5F430083-1980-43AF-9C93-CDB4FE3E57E4

P2860

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

http://www.wikidata.org/entity/Q33607288

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Lithium ameliorates altered gl ...... e model of fragile X syndrome.

@ast

Lithium ameliorates altered gl ...... e model of fragile X syndrome.

@en

type

label

Lithium ameliorates altered gl ...... e model of fragile X syndrome.

@ast

Lithium ameliorates altered gl ...... e model of fragile X syndrome.

@en

prefLabel

Lithium ameliorates altered gl ...... e model of fragile X syndrome.

@ast

Lithium ameliorates altered gl ...... e model of fragile X syndrome.

@en

P1433

Q33607288-7B1A94F5-EA31-4671-BFF8-BD153DEB04A8

P1476

Q33607288-E9C0E913-724C-41F1-9627-313D679E7010

P2093

Q33607288-B1518C3C-DF5C-4038-A4B3-7DCD1159DBD9

Q33607288-C545BE94-BA6E-4C5F-8E61-D31FB5E98994

Q33607288-D3FB42CA-D4F7-437A-B16A-7EB9D29F06CD

P2860

Q33607288-01BFC97A-7FDD-46A1-9622-6924B5B74FB2

Q33607288-03763A93-8874-4414-84E6-14460AADE55D

Q33607288-03DA7455-FA71-40F8-B1B2-6F735FFF1B80

Q33607288-0441908A-F498-4424-9F9E-DB17D237AACA

Q33607288-0EA487D0-8B1C-4974-8891-CF8908BEC0A8

Q33607288-0F2B672C-B0BF-4052-A35E-195BDE61539C

Q33607288-10B10F28-3E72-441A-A549-5C712E416086

Q33607288-10ECB9A6-3BFA-4B29-9E48-EED13CB45212

Q33607288-133AAF55-CE73-4CE2-A68E-3CE72EB6E916

Q33607288-15301EEB-80C7-4F8F-800A-9E90C77D1F28

P304

Q33607288-C64F4B18-00C2-4A4B-A9A4-5E49427225A7

P31

Q33607288-D4EB693D-FAA3-4338-90E6-9F3929E02137

P356

Q33607288-6AD3F91B-4AEF-4F08-BCC0-742904B83991

P407

Q33607288-D4F3E333-B77D-471D-9AAF-75C1785DA13C

P433

Q33607288-0DFB33FA-A026-447B-AE48-1ED76B11B4EA

P478

Q33607288-004F7928-2A19-48A8-86E1-21A04B9F5457

P50

Q33607288-376EFC0E-6C38-4683-98AE-418B4707DAB4

Q33607288-E2709BF8-06D1-4D53-8C2A-CBE061FCE4B9

Q33607288-F122FE06-C199-4BFB-BD82-9D90E8B02800

P577

Q33607288-F4DCA28C-ED14-4E0C-AB3C-E7B24A97630A

P5875

Q33607288-4A6A4A04-5D4D-4B40-8E04-50D455318A22

P698

Q33607288-FD38008C-4535-4908-BFB6-FE1F05F8A0AC

P932

Q33607288-C9DEEAA4-1643-46A6-AA45-CEF645DC4391

P356

J.BCP.2009.09.023

P1433

Biochemical Pharmacology

P1476

Lithium ameliorates altered gl ...... se model of fragile X syndrome

@en

P2093

Margaret K King

http://www.w3.org/2001/XMLSchema#string

Marjelo A Mines

http://www.w3.org/2001/XMLSchema#string

Richard S Jope

http://www.w3.org/2001/XMLSchema#string

P2860

Correction of fragile X syndrome in mice.

Altered synaptic plasticity in a mouse model of fragile X mental retardation

GSK-3: tricks of the trade for a multi-tasking kinase

A molecular mechanism for the effect of lithium on development

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

Specificity and mechanism of action of some commonly used protein kinase inhibitors

Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction

The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers

Essential role of brain-derived neurotrophic factor in adult hippocampal function.

Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors

P304

632-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BCP.2009.09.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Courtney A Miller

J. David Sweatt

Christopher J Yuskaitis

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26866188

http://www.w3.org/2001/XMLSchema#string

P698

19799873

http://www.w3.org/2001/XMLSchema#string

P932

2810609

http://www.w3.org/2001/XMLSchema#string